ADA Medical currently provides research and quality assured based pre-clinical contract services focused on inflammatory, oncology and cardiovascular diseases and will build on Ephoran’s technology.
“The collaboration is a two-way partnership. Ephoran provides cutting edge equipment and facilities, imaging services and in-vivo modeling,” ADA spokesman Daniel Beaulieu told us. “ADA Medical provides clinical research, scientific and program management oversight.”
This new molecular imaging CRO service based near Turin, Italy will conduct pre-clinical drug development modeling and assessments.
ADA Medical’s existing project management, pharmacodynamics, pharmacokinetics, biostatistics, data management and regulatory/quality assurance capabilities will bring needed GLP, pre-clinical management and quality oversight to create the discipline needed for drug research and support of drug research submissions.
“ADA Medical is the exclusive agent for Ephoran,” Beaulieu told us. “All pre-clinical imaging work will be conducted in Italy at Ephoran's facility near Turin. ADA Medical's North American network will provide pre-clinical and scientific reporting.”
Ephoran is a reference centre for a number of imaging technologies and this expansion into drug development aims to fill a void in the pre-clinical drug imaging sector.
“Imaging technology provides significant biological data that will be used to verify the efficacy of a drug compound and make the drug development process much more effective and quicker,” said Vito Lorusso, VP of Ephoran.